Evidence map›Paper›PMID 42184148›Full record

ArticleInternal medicine journal2026

Geographical variability in dabigatran dosing within New Zealand.

Liam T Berryman, Paul K L Chin, Lorna J Pairman, Milan Sundermann, Matthew Doogue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liam T BerrymanDepartment of Medicine, University of Otago, Christchurch, New Zealand.ORCID https://orcid.org/0009-0001-2700-0647
Paul K L ChinDepartment of Medicine, University of Otago, Christchurch, New Zealand.ORCID https://orcid.org/0000-0002-5470-5191
Lorna J PairmanDepartment of Medicine, University of Otago, Christchurch, New Zealand.ORCID https://orcid.org/0000-0002-2436-4277
Milan SundermannDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Matthew DoogueDepartment of Medicine, University of Otago, Christchurch, New Zealand.

Funding

Canterbury Medical Research FoundationUniversity of Otago Future Health Researcher Scholarship
6 · The paper itself

Abstract

Dabigatran etexilate is an oral anticoagulant with increased risk of bleeding at high drug exposure. It is available in three capsule strengths (75, 110 and 150 mg). We analysed New Zealand dispensing data from 2019 to 2023 to compare use between health districts. Overall use was similar across districts. Canterbury had the highest 75 mg use (22.2 vs 1.6-7.6 people per 10 000 in the other districts). This relates to differences in local guidelines, therapeutic drug monitoring and availability of clinical pharmacology services. It is unknown if there are differences in patient outcomes.

Indexed as

AntithrombinsDabigatranAnticoagulantsDose-Response Relationship, DrugDrug MonitoringHumansNew ZealandAnticoagulantsAntithrombinsDabigatrananticoagulantdabigatranNew Zealandpharmacologytherapeutic drug monitoring

Identifiers

PMID42184148
PMCPMC13458212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.